
mAbxience CDMO
Capacidade de uso único de 24.000 L para fabricação de moléculas semelhantes a anticorpos GMP
Compliance: ANVISA (Brazil B-GMP), COFEPRIS, ISO, TITCK (Turkish Health Authorities), ICH, MHRA (UK GMP), ANMAT (Argentina nueva GMP), ISP (Chile BPM), EMA (EU GMP), World Health Organization (GMP / HACCP), UAE Ministry of Health & Prevention, SFDA (Saudi Food & Drug Authority)
Markets: EMA (EU), INVIMA (Colombia), Russian Health Authorities, ANMAT (Argentina), Resto do mundo, COFEPRIS (Mexico), EDE (UAE), ISP (Chile), ANVISA (Brazil), DIGEMID (Peru), Turkish Health Authorities, SFDA (Saudi Arabia)
Batch Size: Large, Medium
Region: LATAM
Use: Human
Services: Analytical / QC services, Manufacturing services
Therapeutic Areas of Expertise (ATC): (B) Blood and blood forming organs, (D) Dermatologicals, (N) Nervous system, (J) Antiinfectives for systemic use, (R) Respiratory system, (P) Antiparasitic products, insecticides and repellents, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (G) Genito urinary system and sex hormones, (C) Cardiovascular system, (A) Digestive tract and metabolism
Category / Product: BIOLOGICS

CONTENT GROUP
COC Farmaceutici srl: sede social; instalação de fabricação.
Category / Product: COSMETICS, CRO ANALÍTICO, FDF / DRUG PRODUCTS, CHEMICAL-SYNTHETIC
Batch Size: Large, Medium
Markets: EMA (EU)
Compliance: ISO, EMA (EU GMP)
Services: Development services, Analytical / QC services, Logistics, Manufacturing services, Quality Assurance services, Regulatory services, Packaging
Use: Human, Veterinary
Therapeutic Areas of Expertise (ATC): (S) Sensory organs, (R) Respiratory system
Region: Europe

CONTENT GROUP
COC Farmaceutici srl: sede comercial e administrativa; instalação de fabricação.
Category / Product: COSMETICS, CRO ANALÍTICO, FDF / DRUG PRODUCTS
Batch Size: Large, Medium
Markets: EMA (EU), MHRA (UK), EDE (UAE), SFDA (Saudi Arabia)
Compliance: ISO
Services: Development services, Analytical / QC services, Logistics, Manufacturing services, Quality Assurance services, Regulatory services, Packaging
Use: Human
Region: Europe

CONTENT GROUP
Tubilux Pharma: sede social; instalação de fabricação.
Batch Size: Large, Medium
Compliance: TITCK (Turkish Health Authorities), ANVISA (Brazil B-GMP), FDA (cGMP), TGA (Australia GMP), Roszdravnadzor (Russia GMP), EMA (EU GMP)
Markets: EMA (EU), Russian Health Authorities, FDA (USA), ANVISA (Brazil), TGA (Australia)
Use: Human, Veterinary
Therapeutic Areas of Expertise (ATC): (S) Sensory organs
Category / Product: CRO ANALÍTICO, FDF / DRUG PRODUCTS
Region: Europe

mAbxience CDMO
Capacidade de uso único de 24.000 L para desenvolvimento de moléculas semelhantes a anticorpos e fabricação de GMP, desde o desenvolvimento de linhagens celulares até substâncias medicamentosas…
Batch Size: Large, Small, Medium
Compliance: TITCK (Turkish Health Authorities), ANVISA (Brazil B-GMP), COFEPRIS, ISO, ICH, FDA (cGMP), PMDA/MHLW (Japan GMP), Health Canada (Canada GMP), MHRA (UK GMP), ANMAT (Argentina nueva GMP), TGA (Australia GMP), Roszdravnadzor (Russia GMP), ECOVADIS, ISP (Chile BPM), French Service-Public (CIR), World Health Organization (GMP / HACCP), EMA (EU GMP), MFDS/KFDA (Republic of Korea GMP), UAE Ministry of Health & Prevention, SFDA (Saudi Food & Drug Authority)
Markets: EMA (EU), MHRA (UK), INVIMA (Colombia), MSPAS (Guatemala), Russian Health Authorities, FDA (USA), PMDA (Japan), Health Canada (Canada), ANMAT (Argentina), Resto do mundo, COFEPRIS (Mexico), EDE (UAE), ISP (Chile), ANVISA (Brazil), DIGEMID (Peru), Turkish Health Authorities, MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia)
Services: Development services, Analytical / QC services, Manufacturing services, Quality Assurance services
Use: Human, Veterinary
Therapeutic Areas of Expertise (ATC): (B) Blood and blood forming organs, (D) Dermatologicals, (N) Nervous system, (J) Antiinfectives for systemic use, (R) Respiratory system, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (H) Systemic hormonal preparations excl. sex hormones and insulins, (G) Genito urinary system and sex hormones, (C) Cardiovascular system, (A) Digestive tract and metabolism
Region: Europe
Category / Product: BIOLOGICS

53Biologics
53Biologics é um CDMO de produtos biológicos de ponta a ponta criado para manter o progresso em movimento, desde o fornecimento pré-clínico até o comercial. Fomos feitos para isso.
Batch Size: Large, Small, Medium
BSL (Biological Safety Level): 1, 2
Compliance: ISO, FDA (cGMP), World Health Organization (GMP / HACCP), EMA (EU GMP)
Markets: FDA (USA), Health Canada (Canada), ANMAT (Argentina), COFEPRIS (Mexico), ISP (Chile), ANVISA (Brazil), DIGEMID (Peru), MSPAS (Guatemala), INVIMA (Colombia), MHRA (UK), EMA (EU), TGA (Australia)
Services: Development services, Analytical / QC services, Logistics, Manufacturing services, Quality Assurance services, Regulatory services
Use: Human, Veterinary
Region: Europe
Category / Product: BIOLOGICS

InClino
Organização europeia de investigação contratual com mais de 20 anos de experiência em investigação clínica e assuntos regulamentares. Ajudamos as terapias a fazer maravilhas.
Markets: EMA (EU)
Services: Development services, Regulatory services
Therapeutic Areas of Expertise (ATC): (V04) Diagnostic agents, (D) Dermatologicals, (J) Antiinfectives for systemic use, (B) Blood and blood forming organs, (V09-10) Radiopharmaceuticals, (N) Nervous system, (S) Sensory organs, (V06) Nutrients, (V01) Allergens, (R) Respiratory system, (P) Antiparasitic products, insecticides and repellents, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (H) Systemic hormonal preparations excl. sex hormones and insulins, (G) Genito urinary system and sex hormones, (C) Cardiovascular system, (A) Digestive tract and metabolism
Category / Product: CRO CLÍNICO, SERVICES
Use: Human
Region: Europe

Bilthoven Biologicals BV
Instalações GMP de vários produtos para substâncias medicamentosas e produtos farmacêuticos.
Markets: EMA (EU), MHRA (UK)
Batch Size: Large, Small, Medium
BSL (Biological Safety Level): 1, 2
Services: Development services, Logistics, Analytical / QC services, Manufacturing services, Quality Assurance services, Regulatory services, Packaging
Use: Human
Compliance: EMA (EU GMP)
Category / Product: FDF / DRUG PRODUCTS, CRO ANALÍTICO, BIOLOGICS
Region: Europe

Polpharma API
Integrated CDMO solutions for HP APIs (OEB 6), ADC payload-linkers and oligonucleotides from development to GMP supply.
Compliance: BRCGS, ISO, ICH, FDA (cGMP), DIGEMID, ANVISA (Brazil B-GMP), MSPAS, COFEPRIS, Roszdravnadzor (Russia GMP), IFS, Halal Research Council, PMDA/MHLW (Japan GMP), TGA (Australia GMP), INVIMA, ECOVADIS, ISP (Chile BPM), TITCK (Turkish Health Authorities), French Service-Public (CIR), ANMAT (Argentina nueva GMP), EMA (EU GMP), NMPA (China GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP), SQF (Safe Quality Food), NSF, UAE Ministry of Health & Prevention, SFDA (Saudi Food & Drug Authority)
Markets: FDA (USA), EMA (EU), PMDA (Japan), NMPA (China), Health Canada (Canada), MHRA (UK), MFDS (South Korea)
Batch Size: Large, Small, Medium
Services: Development services, Analytical / QC services, Manufacturing services, Quality Assurance services, Regulatory services
Therapeutic Areas of Expertise (ATC): (N) Nervous system, (B) Blood and blood forming organs, (D) Dermatologicals, (J) Antiinfectives for systemic use, (M) Musculoskeletal system, (G) Genito urinary system and sex hormones, (C) Cardiovascular system, (A) Digestive tract and metabolism
Category / Product: PARTICLE ENGINEERING, SERVICES, CHEMICAL-SYNTHETIC, OLIGONUCLEOTIDES
Use: Human
OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 5,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 5,000 µg/day)
Region: Europe

Seacross Pharmaceutical Co Ltd
O Centro de P&D desempenha um papel fundamental no apoio ao desenvolvimento tanto de APIs quanto de formas farmacêuticas acabadas.
Markets: ISP (Chile), MSPAS (Guatemala), FDA (USA), COFEPRIS (Mexico), DIGEMID (Peru), EMA (EU), PMDA (Japan), NMPA (China), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), Russian Health Authorities, SFDA (Saudi Arabia), ANMAT (Argentina), CDSCO (India), MFDS (South Korea), INVIMA (Colombia), Turkish Health Authorities, EDE (UAE), TGA (Australia), Resto do mundo
Batch Size: Large, Small, Medium
Compliance: FDA (cGMP), DIGEMID, BRCGS, ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), MSPAS, COFEPRIS, Roszdravnadzor (Russia GMP), IFS, Halal Research Council, INVIMA, TGA (Australia GMP), TITCK (Turkish Health Authorities), ECOVADIS, ISP (Chile BPM), French Service-Public (CIR), Health Canada (Canada GMP), MHRA (UK GMP), ANMAT (Argentina nueva GMP), World Health Organization (GMP / HACCP), EMA (EU GMP), NMPA (China GMP), MFDS/KFDA (Republic of Korea GMP), NSF, SQF (Safe Quality Food), UAE Ministry of Health & Prevention, SFDA (Saudi Food & Drug Authority)
Services: Development services, Logistics, Analytical / QC services, Manufacturing services, Quality Assurance services, Regulatory services, Packaging
Use: Human
BSL (Biological Safety Level): 1, 2, 3, 4
Therapeutic Areas of Expertise (ATC): (V04) Diagnostic agents, (N) Nervous system, (S) Sensory organs, (V09-10) Radiopharmaceuticals, (B) Blood and blood forming organs, (D) Dermatologicals, (J) Antiinfectives for systemic use, (V06) Nutrients, (V01) Allergens, (R) Respiratory system, (P) Antiparasitic products, insecticides and repellents, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (H) Systemic hormonal preparations excl. sex hormones and insulins, (G) Genito urinary system and sex hormones, (C) Cardiovascular system, (A) Digestive tract and metabolism
Controlled Substances: Lowest potential for abuse, Lower potential for abuse, High potential for abuse & no medical use, Low potential for abuse, High potential for abuse & medical use
OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 5,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 5,000 µg/day)
Category / Product: FDF / DRUG PRODUCTS, CHEMICAL-SYNTHETIC
Region: APAC

Aenova
Centro de Competência Sólidos de baixa dosagem e alta potência (hormônios, semelhantes a hormônios), cápsulas de baixa dosagem.
Use: Human, Veterinary
Markets: FDA (USA), EMA (EU), ANVISA (Brazil), Russian Health Authorities, MFDS (South Korea), Turkish Health Authorities
Services: Development services, Analytical / QC services, Regulatory services, Packaging, Manufacturing services, Quality Assurance services
Batch Size: Large, Small, Medium
Compliance: FDA (cGMP), ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), TITCK (Turkish Health Authorities), EMA (EU GMP), MFDS/KFDA (Republic of Korea GMP)
OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 5,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 5,000 µg/day)
Category / Product: FDF / DRUG PRODUCTS
Therapeutic Areas of Expertise (ATC): (H) Systemic hormonal preparations excl. sex hormones and insulins
Region: Europe

Seacross Pharmaceutical Co Ltd
O Centro de Fabricação de Formulações é dedicado ao desenvolvimento e produção de formas farmacêuticas complexas e de alto valor.
Markets: Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), FDA (USA), EMA (EU), PMDA (Japan), NMPA (China), DIGEMID (Peru), MHRA (UK), Russian Health Authorities, CDSCO (India), Turkish Health Authorities, EDE (UAE), SFDA (Saudi Arabia), ANMAT (Argentina), INVIMA (Colombia), MFDS (South Korea), TGA (Australia), Resto do mundo
Batch Size: Large, Small, Medium
Use: Human
BSL (Biological Safety Level): 1, 2, 3, 4
Compliance: ISO, FDA (cGMP), DIGEMID, BRCGS, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), MSPAS, COFEPRIS, Roszdravnadzor (Russia GMP), IFS, Halal Research Council, TGA (Australia GMP), TITCK (Turkish Health Authorities), INVIMA, ECOVADIS, ISP (Chile BPM), French Service-Public (CIR), World Health Organization (GMP / HACCP), NMPA (China GMP), Health Canada (Canada GMP), MHRA (UK GMP), ANMAT (Argentina nueva GMP), EMA (EU GMP), MFDS/KFDA (Republic of Korea GMP), NSF, SQF (Safe Quality Food), UAE Ministry of Health & Prevention, SFDA (Saudi Food & Drug Authority)
Services: Development services, Logistics, Analytical / QC services, Manufacturing services, Quality Assurance services, Regulatory services, Packaging
Therapeutic Areas of Expertise (ATC): (V04) Diagnostic agents, (B) Blood and blood forming organs, (D) Dermatologicals, (J) Antiinfectives for systemic use, (N) Nervous system, (S) Sensory organs, (V06) Nutrients, (V01) Allergens, (R) Respiratory system, (P) Antiparasitic products, insecticides and repellents, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (H) Systemic hormonal preparations excl. sex hormones and insulins, (G) Genito urinary system and sex hormones, (C) Cardiovascular system, (A) Digestive tract and metabolism
Controlled Substances: Lowest potential for abuse, Lower potential for abuse, High potential for abuse & no medical use, Low potential for abuse, High potential for abuse & medical use
OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 5,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 5,000 µg/day)
Category / Product: FDF / DRUG PRODUCTS, CRO ANALÍTICO
Region: APAC
Registe-se para desbloquear o catálogo completo com detalhes de contacto e locais.
+96 mais instalações
Criar Conta GRATUITAAre you a pharmaceutical company seeking a reliable CMO or CDMO partner to accelerate your drug development process? Look no further than MAI CDMO Network. Our advanced search platform connects you with a vast network of qualified contract manufacturers and development organizations worldwide.
Why Choose MAI CDMO Network?
How MAI CDMO Network Works
Key Benefits of Partnering with a CMO/CDMO
Featured Services
Ready to Find Your Ideal CMO/CDMO Partner? Register Now
Explore our platform today and discover how MAI CDMO Network can help you achieve your drug development goals.